H. Trautman

A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US.

D. Esseltine, J. L. Marantz, D. Fullerton, 2007 .

Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.

B. Tang, E. Szabó, H. Trautman, 2019, Journal of managed care & specialty pharmacy.

Scales for Assessing Nonmotor Symptom Severity Changes in Parkinson's Disease Patients With Symptom Fluctuations

P. Buck, H. Trautman, Jamie Clark, 2010, The International journal of neuroscience.

Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility

S. Thompson, R. Ribalov, H. Trautman, 2021, ClinicoEconomics and outcomes research : CEOR.